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license (http://creativeAlzheimer’s disease (AD) markers differs in men and women across AD stages.
Methods: Among normal control (NC) participants (N5 702) and participants with mild cognitive
impairment (N 5 576) and AD (N 5 305), we examined the associations of sex and APOE-ε4
carrier status with cortical amyloid-b (Ab) burden, hippocampal volume ratio (HpVR; hippocampal
volume/intracranial volume! 103), brain glucose metabolism, and verbal memory.
Results: In NC, APOE-ε4 related to greater Ab burden and poorer verbal memory across sex but to
smaller HpVR and hypometabolism in men only. In mild cognitive impairment, APOE-ε4 related to
smaller HpVR, hypometabolism, greater Ab burden, and poorer verbal memory across sex. In AD,
APOE-ε4 related to greater Ab burden in men only and smaller HpVR across sex and showed no
association with hypometabolism or verbal memory.
Discussion: Sex differences in the association betweenAPOE-ε4 andADmarkers vary by disease stage.
 2018 TheAuthors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open
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The ε4 allele of the apolipoprotein E gene (APOE-ε4) is
the most common genetic risk factor for Alzheimer’s disease
(AD) [1,2]. APOE-ε4 is associated with AD-related
biological and clinical markers including cortical amyloid-b
(Ab) plaque burden, hippocampal atrophy [3–5], and
accelerated cognitive decline in healthy aging [6–8].
However, there have been conflicting/mixed findings with
some reporting that APOE-ε4 is not associated with
hippocampal volume [9,10] or cognitive decline in healthy
aging [9,10] or with risk of converting from mild cognitive
impairment (MCI) to AD [11,12]. These inconsistencies
may be due to the potentially critical modulating role of sex
in the association between APOE-ε4 and AD.imer’s Association. This is an open access article under the CC BY-NC-ND
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confers a greater risk for AD in women than in men
[13–15]. These early findings are supported by a
longitudinal study [16] and a meta-analysis that reported
an increased risk of incident AD in female APOE-ε4
heterozygotes versus male heterozygotes among adults
aged 65 to 75 years [17]. Among older normal controls,
the adverse effect of APOE-ε4 on AD biomarkers including
cerebrospinal fluid total tau levels [18], brain metabolism
[19], cortical thinning [19], and functional brain
connectivity in the default mode network [18] was stronger
in women versus men, although not consistently [19,20]. In
MCI, the effect of APOE-ε4 on brain atrophy [21], total tau
levels [16], and the tau/Ab ratio [16] was stronger in women
versus men. To our knowledge, only one study examined sex
differences in the effects of APOE-ε4 in AD patients and
reported a stronger association between APOE-ε4 and Ab
burden in parietal, cingulate, and frontal regions in men
versus women [22], suggesting a possible reversal in the
moderating role of sex on APOE-ε4 in the MCI-to-AD
transition that warrants further exploration.
Surprisingly, few studies have examined the interactive
effects of sex and APOE-ε4 on cognitive performance
[21,23,24], particularly verbal memory, even though
verbal memory is the cognitive domain that shows the
earliest and most severe deficits in AD [25]. Among
community-dwelling older adults, the association between
APOE-ε4 and accelerated cognitive decline, as measured
by a global cognitivemeasure, was stronger in womenversus
men [23,24]. In a MCI sample, female heterozygous or
homozygous APOE-ε4 carriers showed worse performance
on a delayed (5 minute) word recall task from the
Alzheimer’s Disease Assessment Scale Cognitive Subscale
compared with female noncarriers, whereas the APOE-ε4
effect was only evident in homozygous men [21]. In
addition, few studies have examined the sex by APOE
interaction across the AD continuum [22] despite evidence
of a temporal ordering of AD markers, whereby Ab
deposition occurs first, followed by neurodegenerative
biomarkers and cognitive impairment [26,27]. We
systematically examined the separate and interactive
effects of sex and APOE on multiple AD-related markers
including Ab deposition, hippocampal volume, brain
glucose metabolism, and verbal memory performance in
the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database. Effects were examined in each disease stage
(NC, MCI, AD), in which MCI versus NC was defined
using the Jak/Bondi diagnostic method, an actuarial,
neuropsychological diagnostic approach that has produced
more discernible cognitive phenotypes, more stable
diagnoses, stronger associations with AD biomarkers, and
better predication of progression to dementia than
conventional diagnostic criteria [28,29]. Consistent with
the broader literature, we predicted that the adverse effects
of APOE-ε4 would be stronger in women versus men, and
in-line with the temporal sequence of AD-related markers[26,27], this sex difference in the APOE-ε4 effect will
manifest at the NC stage for earlier AD events
(Ab deposition) and in MCI for later events (hippocampal
atrophy, brain hypometabolism, and memory deficits).2. Methods
2.1. Participants and data source
Data were extracted from the ADNI database (adni.loni.
usc.edu). ADNI is a longitudinal, multisite cohort study
that began in 2003 as a public-private partnership.
Information about ADNI can be found at www.adni-info.
org. ADNI study visits involve neuroimaging, neuropsycho-
logical, and clinical assessments. We included participants
who had APOE genotype and baseline data on one of the
AD-related markers examined herein. We limited our
sample to ADNI’s largest race/ethnic group, Caucasians, to
minimize potential population stratification bias that could
complicate interpretation of genetic data. Analyses were
repeated while excluding APOE-ε2 allele carriers because
the protective effect of APOE-ε2 could mask the adverse
effect of APOE-ε4.
2.2. Verbal memory assessment
Our verbal memory measure was the Rey Auditory
Verbal Learning Test (AVLT) [30]. The AVLT is a multitrial
list learning and memory test with immediate and delayed
recall and recognition outcomes. Immediate recall scores
(range: 0–75) were the primary outcome because they
were not used in diagnostic criteria, and learning deficits
may better discriminate preclinical AD from normal
controls than retention deficits [31,32].
2.3. Biomarkers
Biomarkers included neuroimaging measures of
hippocampal volume, brain glucose metabolism, and
cortical Ab deposition. Structural MRI scans were collected
on a 1.5T scanner according to a standardized protocol [33].
Hippocampal volume data were analyzed using FreeSurfer
version 4.3 (https://surfer.nmr.mgh.harvard.edu) at the Uni-
versity of California–San Francisco (http://adni.loni.ucla.
edu/wp-content/uploads/2010/12/UCSF-FreeSurfer-Overview-
and-QC_-Template_Format.pdf) [34]. To control for sex
differences in head size, we calculated a hippocampal
volume ratio (HpVR) using the formula, hippocampal/
intracranial volume! 103.
Brain glucose metabolism was measured by [18F]
fludeoxyglucose (FDG) positron emission tomography
(PET). Images were preprocessed following a standard
procedure described in http://adni.loni.usc.edu/methods/
pet-analysis/pre-processing/. ADNI investigators at the
University of California, Berkeley, established a “MetaROI”
of brain regions that commonly demonstrate metabolic
changes in MCI/AD which correlate with cognitive
Table 1
Sample size by sex, APOE-ε4 status, and diagnostic group for each AD-
related marker
Diagnostic group/outcome
Total
sample
APOE-ε41 APOE-ε42
Women Men Women Men
NC
AVLT Immediate Recall 702 107 126 228 241
HpVR 630 101 109 205 215
FDG SUVR 562 88 101 180 193
AV45 SUVR 430 78 71 143 138
MCI
AVLT Immediate Recall 576 127 183 101 165
HpVR 490 112 152 84 142
FDG SUVR 414 87 135 73 119
AV45 SUVR 260 58 78 52 72
AD
AVLT Immediate Recall 305 90 120 45 58
HpVR 250 73 97 36 44
E.E. Sundermann et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 438-447440performance in a meta-analysis [11,35]. The “MetaROI”
was comprised of bilateral posterior cingulate gyrus,
bilateral angular gyri, and middle/inferior temporal
gyrus. Standardized uptake value ratios (SUVRs)
were calculated by averaging FDG uptake across the
MetaROI and dividing by a reference region of
pons and cerebellum [11,35]. FDG PET image analysis is
described in http://www.adni-info.org/Scientists/ADNIStudy
Procedures.aspx.
Cortical Ab burden was measured by [18F]florbetapir
positron emission tomography (AV45 PET) as described
in http://www.adni-info.org. Mean AV45 uptake was
measured within frontal, anterior/posterior cingulate, lateral
parietal, and lateral temporal regions. SUVRs were
calculated by averaging across regions and dividing by
whole cerebellum.FDG SUVR 220 63 83 25 49
AV45 SUVR 130 39 48 15 28
Abbreviations: AD, Alzheimer’s disease; APOE-ε4, apolipoprotein ε4
allele; AV45, florbetapir positron emission tomography; AVLT, Rey Audi-
tory Verbal Learning Test; FDG, fluodeoxyglucose; HpVR, hippocampal
volume ratio (hippocampal/intracranial volume ! 103); MCI, mild
cognitive impairment; NC, normal control; SUVR, standardized uptake
value ratio.2.4. Diagnostic classification
Diagnosis of NC versus MCI was based on the Jak/Bondi
diagnostic method [28]. This method included six
neuropsychological tests representing three cognitive
domains: (1) Trail-Making Tests A and B (psychomotor
speed/executive function); (2) Category Fluency and Boston
Naming Test (language); and (3) AVLT Delayed Recall and
Recognition Tests (episodic memory). An impaired score
was defined as .1 SD below the age-corrected normative
mean. MCI diagnosis required one of three criteria:
(1) impaired score on two tests within a cognitive domain;
(2) one impaired score in each of the three cognitive
domains; and/or (3) a score of 9 on the Functional
Assessment Questionnaire indicating dependence in at least
three daily activities. If no criterion was met, a NC diagnosis
was provided. Diagnostic criteria for AD were based on
the standard National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association criteria [36].2.5. Statistical analysis
The APOE genotype was categorized into APOE-ε4
carriers and noncarriers because of the low prevalence of
APOE-ε4 homozygotes when stratifying by sex and
diagnostic group (e.g., 8 women and 22 men in NC group).
Analyses were conducted within diagnostic group.
Differences in sample characteristics and AD-related markers
between sex and APOE-ε4 status were examined using
independent t-tests for continuous variables and Chi-square
tests for categorical variables. We used multivariable linear
regression analyses modeling the separate and interactive
associations of sex and APOE-ε4 status with each
AD-associated marker (HpVR, FDG SUVR, AV45 SUVR,
and AVLT scores) while adjusting for age and education.
The interaction was removed from the model if P  .10.
Analyses were performed using SPSS 24 (SPSS Inc.,
Chicago, IL). Significancewas defined asP .05 (two-sided).3. Results
Our sample included 1583 participants with AVLT
scores, 1370 with HpVR, 998 with FDG SUVR, and
820 with AV45 SUVR. Table 1 displays sample sizes by
sex and APOE-ε4 status for each diagnostic group and
AD-related marker. In the largest sample (participants with
AVLT scores), there were no sex differences in the
distribution of APOE-ε4 carriers in any diagnostic group.
In all diagnostic groups, women were younger and had
less years of education than men (P’s , .05; Table 2).
Mean Mini-Mental State Examination score was higher in
NC women versus NC men (P 5 .002), although the
difference was only half a point. APOE-ε4 carriers were
younger than noncarriers in all diagnostic groups
(P , .01). APOE-ε4 carriers had a lower mean
Mini-Mental State Examination and a higher mean Clinical
Dementia Rating–Sum of Boxes socres than noncarriers in
MCI (P , .001). Differences between sex and APOE-ε4
status groups on AD-related markers are examined in the
linear regressions that are described in the following.3.1. Normal control
Inconsistent with hypotheses, there was a significant sex
by APOE interaction on HpVR (Table 3) and FDG SUVR in
NC (Fig. 1). The APOE-ε4 allele was associated
with smaller HpVR and lower FDG SUVR in men
(HpVR: B 5 20.26, SE 5 0.07, P , .001; FDG
SUVR: B 5 20.06, SE 5 0.02, P , .001) but not in
women (HpVR: B 5 0.01, SE 5 0.07, P 5 .86; FDG
SUVR: B 5 20.01, SE 5 0.01, P 5 .33). The interaction
Table 3
Results of multivariable linear regression analyses modeling the separate and interactive associations of sex and APOE-ε4 status with AD-related markers
Sample/outcome
Multivariable linear regression models
Sex (male versus female)
APOE-ε4 (ε4 carriers versus
noncarriers) status Sex! APOE-ε4 status
B, b (SE) P value B, b (SE) P value B, b (SE) P value
NC
HpVR 20.16, 20.12 (0.06) .007 0.02, 0.01 (0.07) .81 20.28, 20.16 (0.1) .004
FDG SUVR 20.02, 20.10 (0.01) .04 20.02, 20.06 (0.01) .29 20.04, 20.15 (0.02) .02
AV45 SUVR 20.04, 20.18 (0.01) ,.001 20.03, 20.18 (0.01) .002 0.01, 0.02 (0.03) .78
AVLT Immediate Recall 27.33, 20.36 (0.69) ,.001 21.46, 20.07 (0.71) .04 21.55, 20.06 (1.42) .27
MCI
HpVR 0.01, 0.03 (0.01) .60 20.25, 20.18 (0.01) ,.001 0.05, 0.03 (0.13) .69
FDG SUVR 20.01, 20.09 (0.02) .22 20.08, 20.30 (0.02) ,.001 0.04, 0.15 (0.03) .11
AV45 SUVR 0.00, 0.00 (0.03) .99 0.21, 0.45 (0.03) ,.001 20.09, 20.18 (0.05) .09
AVLT Immediate Recall 23.29, 20.20 (0.67) ,.001 22.79, 20.17 (0.65) ,.001 0.39, 0.02 (1.33) .77
AD
HpVR 20.20, 20.16 (0.08) .008 20.23, 20.17 (0.08) .004 0.05, 0.04 (0.16) .76
FDG SUVR 20.01, 20.04 (0.02) .55 0.02, 0.05 (0.02) .40 20.01, 20.05 (0.04) .74
AV45 SUVR 20.21, 20.49 (0.06) .001 0.03, 0.07 (0.06) .61 0.20, 0.45 (0.07) .007
AVLT Immediate Recall 22.70, 20.18 (0.89) .003 1.04, 0.07 (0.90) .25 22.29, 20.15 (1.78) .20
Abbreviations: AD, Alzheimer’s disease; APOE-ε4, apolipoprotein ε4 allele; AV45 PET, florbetapir positron emission tomography; AVLT, Rey Auditory
Verbal Learning Test; B, unstandardized regression coefficient; FDG, fluodeoxyglucose; HpVR, hippocampal volume ratio (hippocampal/intracranial volume
! 103); MCI, mild cognitive impairment; NC, normal controls; SUVR, standardized uptake value ratio; b, standardized regression coefficient.
NOTE. All analyses were adjusted for age and education. Bolded text indicates statistical significance at P , .05.
Table 2
Characteristics of each diagnostic group as a function of sex and APOE-ε4 status
Parameters
Sex
Women versus
men P value
APOE-ε4 status
APOE-ε41 versus
APOE-ε42 P valueWomen Men APOE-ε41 APOE-ε42
NC
Age 73.0 (6.6) 74.1 (6.9) .01 72.4 (6.9) 74.1 (6.7) .001
Education, years 15.8 (2.6) 17.0 (2.5) ,.001 16.2 (2.5) 16.5 (2.6) ns
MMSE 28.9 (1.3) 28.6 (1.5) .002 28.6 (1.6) 28.8 (1.3) ns
AVLT Immediate Recall 47.7 (8.9) 44.1 (10.1) ,.001 43.4 (10.6) 44.5 (9.8) ns
HpVR 5.0 (0.6) 4.7 (0.7) ,.001 4.8 (0.7) 4.9 (0.7) ns
FDG SUVR 1.32 (0.11) 1.29 (0.12) ,.001 1.28 (0.12) 1.31 (0.11) .002
AV45 SUVR 1.2 (0.2) 1.1 (0.2) .04 1.2 (0.2) 1.1 (0.2) ,.001
MCI
Age 72.5 (7.4) 74.5 (6.8) .003 72.9 (6.7) 74.6 (7.4) ,.001
Education, years 15.4 (2.8) 16.2 (2.8) .003 15.8 (2.9) 15.9 (2.7) ns
MMSE 27.4 (1.9) 27.4 (1.8) ns 27.2 (1.8) 27.7 (1.8) ,.001
CDR-SOB 1.5 (1.0) 1.6 (1.0) ns 1.7 (1.0) 1.4 (1.0) ,.001
AVLT Immediate Recall 32.6 (8.7) 29.3 (7.5) ,.001 29.5 (7.7) 31.9 (8.5) ,.001
HpVR 4.4 (0.8) 4.2 (0.7) .005 4.2 (0.8) 4.4 (0.7) .02
FDG SUVR 1.22 (0.14) 1.22 (0.13) ns 1.20 (0.13) 1.24 (0.13) .002
AV45 SUVR 1.2 (0.2) 1.3 (0.2) ns 1.3 (0.2) 1.1 (0.2) ,.001
AD
Age 73.8 (7.9) 76.0 (7.6) .03 74.1 (7.2) 76.8 (8.6) .005
Education, years 14.4 (2.6) 16.0 (2.8) ,.001 15.2 (2.8) 15.5 (2.8) ns
MMSE 23.3 (2.1) 23.2 (2.0) ns 23.4 (2.0) 23.1 (2.1) ns
CDR-SOB 4.5 (1.7) 4.4 (1.6) ns 4.3 (1.6) 4.6 (1.8) ns
AVLT Immediate Recall 23.8 (7.9) 21.5 (6.8) .03 22.8 (7.0) 21.9 (8.0) ns
HpVR 3.9 (0.7) 3.7 (0.6) .02 3.7 (0.5) 3.9 (0.8) .05
FDG SUVR 1.06 (0.15) 1.07 (0.14) ns 1.07 (0.14) 1.07 (0.15) ns
AV45 SUVR 1.5 (0.2) 1.4 (0.2) .001 1.5 (0.2) 1.3 (0.3) ,.001
Abbreviations: AD, Alzheimer’s disease; APOE-ε4, apolipoprotein ε4 allele; AV45, florbetapir positron emission tomography; AVLT, Rey Auditory Verbal
Learning Test; CDR-SOB, Clinical Dementia Rating–Sum of Boxes; FDG, fluodeoxyglucose; HpVR, hippocampal volume ratio (hippocampal/intracranial
volume! 103); MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NC, normal control; SUVR, standardized uptake value ratio.
NOTE. Values are expressed as mean (standard deviation). Sample characteristics are based on the largest sample (participants with AVLT Immediate Recall
data). The pattern of sex and APOE-ε4 status differences in sample characteristics was similar in all AD marker subsamples.
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Fig. 1. Mean AD biomarkers (A–C) and AVLT Immediate Recall scores (D) as a function of sex and APOE-ε4 status in NC. *Significant mean difference at
P , .05 while adjusting for age and education. Abbreviations: APOE41, apolipoprotein ε4 allele carrier; APOE42, apolipoprotein ε4 allele noncarrier;
AVLT score, Immediate Recall outcome of the Rey Auditory Verbal Learning Test (range, 0–75); FDG, fludeoxyglucose; HpVR, hippocampal volume ratio;
SUVR, standardized uptake volume ratio.
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Rather, there was a main effect of sex and APOE-ε4 for
both markers in NC; however, as seen in Fig. 1D, the adverse
effect of APOE-ε4 on AVLT scores was only significant
among NC men in sex-stratified analyses. Women
demonstrated higher AVLT scores and AV45 SUVR than
men (P  .001), and APOE-ε4 carriers demonstrated higher
AV45 SUVR and lower AVLT scores than noncarriers
(P , .05).A
B
C 
D 
3.2
3.7
4.2
4.7
5.2
Women Men
APOE4+ APOE4-
1.01
1.06
1.11
1.16
1.21
1.26
1.31
1.36
Women Men
APOE4+ APOE4-
M
ea
n 
H
pV
R
M
ea
n 
FD
G
 S
U
V
R
*
* *
p=.06
Fig. 2. Mean AD biomarkers (A–C) and AVLT Immediate Recall scores (D) as a
P , .05 while adjusting for age and education. Abbreviations: APOE41, apoli
AVLT score, Immediate Recall outcome of the Rey Auditory Verbal Learning Tes
SUVR, standardized uptake volume ratio.3.2. Mild cognitive impairment
In the MCI sample, there were no significant sex by APOE
interactions on any AD-related marker (Fig. 2). There was a
main effect of sex on AVLT scores in MCI whereby scores
were higher in women than in men (P , .001). There was a
main effect of APOE-ε4 for all markers in MCI. APOE-ε4
was associatedwith smaller HpVR, lower FDGSUVR, higher
AV45 SUVR, and poorer AVLT scores (P’s , .001).0.4
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Fig. 3. Mean AD biomarkers (A–C) and AVLT Immediate Recall scores (D) as a function of sex and APOE-ε4 status in AD. *Significant mean difference at
P , .05 while adjusting for age and education. Abbreviations: APOE41, apolipoprotein ε4 allele carrier; APOE42, apolipoprotein ε4 allele noncarrier;
AVLT score, Immediate Recall outcome of the Rey Auditory Verbal Learning Test (range, 0–75); FDG, fludeoxyglucose; HpVR, hippocampal volume ratio;
SUVR, standardized uptake volume ratio.
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Among AD patients, there was a significant sex by APOE
interaction on AV45 SUVR (P5 .007; Fig. 3). APOE-ε4 was
associated with a higher AV45 SUVR in men (B 5 0.23,
SE 5 0.05, P , .001) but not in women (B 5 0.02,
SE 5 0.05, P 5 .67). The interaction was not significant
for the other markers. As in the other diagnostic groups,
there was a main effect of sex on AVLT scores in AD.
AVLT scores were higher in women versus men
(P 5 .003). There was also a main effect of sex on HpVR
and AV45 SUVR in AD. HpVR and AV45 SUVR were
higher in women versus men (P , .01). There was no
main effect of sex on FDG SUVR. There was a main effect
of APOE-ε4 on HpVR in AD. HpVR was lower in APOE-ε4
carriers versus noncarriers (P 5 .004). There were no main
effects of APOE-ε4 on other markers.
When excluding APOE-ε2 carriers, results were
unchanged in the NC and AD groups. In contrast to the
primary results, the sex by APOE interaction was significant
for FDG SUVR (B 5 0.05, SE 5 0.03, P 5 .05) in MCI.
APOE-ε4 was associated with lower FDG SUVR in
MCI women (B 5 20.09, SE 5 0.02, P , .001) but not in
MCI men (B 5 20.03, SE 5 0.02, P 5 .13). In addition,
there was a significant sex by APOE interaction for AV45
SUVR in MCI (B 5 20.11, 0.06, P 5 .04). The APOE-ε4
and AV45 SUVR association was stronger in MCI women
(B 5 0.26, SE 5 0.04, P , .001) versus MCI men
(B 5 0.16, SE 5 0.04, P , .001).
4. Discussion
Broadly, our findings support evidence of sex differ-
ences in the adverse effect of APOE-ε4 on AD-relatedmarkers. We extend previous findings by performing the
following: (1) comparing these sex differences across
biomarker and clinical outcomes; (2) identifying changes
in sex differences that occur across disease stages;
and (3) by defining MCI using an algorithmic,
neuropsychological diagnostic criteria that have shown
better prognostic value in terms of progression to dementia
than more conventional criteria. Our novel findings are that
sex differences in APOE-ε4 effects on AD-related markers
varied by marker and disease stage and that the effect of
APOE-ε4 on brain structure/function manifested at a later
disease stage in women versus men.
Consistent with previous findings, we found that AV45
SUVR was higher in NC women versus NC men regardless
of APOE genotype. We also replicated the well-evidenced
finding that women outperform men in verbal memory and
indicated that this difference is regardless of APOE
genotype. The dichotomy of better verbal memory
performance and greater Ab pathology in NC women versus
NC men suggests that women may be better equipped to
compensate for disease pathology and maintain normal
verbal memory performance. Consistent with some past
reports [37–40], we also found that NC women had a
larger HpVR and a higher FDG SUVR than NC men
possibly because of hormonal factors associated with
female sex, such as the organization and activation effects
of estrogen on the brain. A larger and a more efficient
neural network in the brain region that regulates verbal
memory may serve as a “brain reserve” [41,42] that allows
for compensation of the greater Ab deposition in women
and supports the female advantage in verbal memory.
Inconsistent with hypotheses, sex by APOE interactions on
HpVR and FDG PET in the NC group indicated an
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SUVR in men only. The association between APOE and
brain structure/function in healthy aging has been
controversial with some, but not all, studies reporting an
association [19,43–47]. Neglecting APOE by sex
interactive effects on brain structure/function could be a
contributing factor to discordant results.
The sex differences in FDG SUVR, Ab deposition, and
HpVR (after adjusting for covariates) observed in NC
were absent in MCI; however, women were able to sustain
their verbal memory advantage over men in MCI despite
poorer AVLT scores in MCI versus NC. In contrast to the
NC group, the adverse effects of APOE-ε4 on HpVR and
FDG SUVR were observed in MCI women in addition to
MCI men. Findings suggest that whereas APOE- 34 effects
on brain structure/function manifest in men during normal
cognitive aging or preclinical AD, effects do not manifest
in women until MCI. Perhaps, in the MCI stage, the
pathophysiological brain changes have reached a threshold
of severity past which compensatory mechanisms are
overwhelmed in women and the adverse effect of APOE-ε4
on verbal memory is exposed. Conversely, the adverse effect
of APOE-ε4 on higher amyloid deposition was observed
across sex in both NC and MCI possibly because of the
hypothesized temporal evolution of AD biomarkers whereby
Ab deposition occurs before changes in brain structure
and functional changes and up to a decade before clinical
deficits [48].
In AD, overall sex differences included a larger HpVR
and the continued female advantage in verbal memory
advantage in women versus men although the sex difference
in AVLT scores was much smaller than that observed in the
NC and MCI groups suggesting that the advantage is
attenuated with increasing disease severity.APOE-ε4 related
to smaller HpVR and greater Ab deposition but not FDG
SUVR or verbal memory in AD suggesting that the effects
of the disease at this advanced stage overwhelm APOE-ε4
effects on brain function and verbal memory. There was a
sex by APOE interaction on AV45 SUVR in AD whereby
APOE-ε4 related to AV45 SUVR in men only. As shown
in Figs. 2C and 3C, the manifestation of this interaction in
AD but not in MCI resulted from greater Ab deposition in
female APOE-ε4 noncarriers in AD versus MCI so that Ab
deposition was similarly high in female carriers and
noncarriers with AD. Conversely, male noncarriers had
similar Ab deposition levels in MCI and AD. Similarly,
Tosun et al. [22] reported a sex by APOE interaction on
Ab deposition that was driven by lower Ab deposition in
male APOE-ε4 noncarriers versus carriers and similarly
high levels in female carriers and noncarriers. An increase
in Ab deposition in female noncarriers in the MCI-to-AD
transition requires investigation in longitudinal studies
and, if found, would challenge theories that Ab deposition
plateaus before AD diagnosis in women [48].
Our results are in contrast to some previous reports of a
stronger APOE effect in women versus men on AD-relatedoutcomes in healthy aging and on cognitive function in
MCI. Discrepant findings may result from multiple
contributing factors. Mixed race/ethnicity groups in prior
studies may have introduced bias from population
stratification that can complicate interpretation of genetic
data. Race differences have been reported in the effects of
APOE-ε4 on cognitive decline [49]. Studies may also have
differed in the age of study samples and the specific
biomarkers (e.g., cortical thickness vs. ROI-based
volumetry) or cognitive outcomes examined. Many studies
examined a global cognitive measure, whereas we
specifically examined verbal memory, a clinical marker
more reflective of AD risk. The female advantage on verbal
memory may influence the effect of APOE on verbal
memory. Differences in diagnostic criteria might also
contribute to discrepant findings. We used the Jak/Bondi
criteria, an actuarial neuropsychological diagnostic
approach that eliminates use of rating scales, global
cognitive screens, and subjective cognitive complaints that
are commonly used in conventional diagnostic methods.
When comparing Jak/Bondi and conventional criteria,
conventional MCI diagnostic methods resulted in about
33% false-positive and 7% false-negative error rates
[28,29,50]. In support of the Jak/Bondi criteria, the
“false-positive” subgroup performed within normal limits
across the cognitive battery and showed cerebrospinal fluid
biomarker levels, cortical thickness maps, and rates of
progression to dementia that were comparable to a robust
NC group [28,29,51]. The “false-negative” group showed
cerebrospinal fluid biomarker levels that were comparable
to the MCI group and progressed to dementia at double
the rate of the overall NC sample [50]. These diagnostic
errors resulting from conventional diagnoses may have
skewed results of prior studies of sex by APOE interactive
effects within NC or MCI.
Our study has limitations. Our cross-sectional design
precluded us from comparing rates of biomarker
progression and memory decline by sex and APOE-ε4
status. Our differing and, at times, small sample sizes
for each marker and diagnostic group may have led to
varying and limited degrees of statistical power; however,
we were able to detect a significant sex by APOE
interaction in the smallest sample (AD patients with
AV45 SUVR data). Our statistical power was too limited
for significant findings to survive a multiple comparison
correction; however, we sought to minimize comparisons
by conducting sex-stratified analyses only in the
presence of a significant sex by APOE-ε4 interaction.
The risk for type 1 error should be considered when
interpreting results. Our low number of APOE-ε4
homozygotes prohibited us from examining the additive
effects of APOE-ε4 (noncarriers vs. heterozygotes vs.
homozygotes). Finally, ADNI participants represent a
convenience sample of volunteers who are predominantly
Caucasian and well educated, which limits generali-
zability of results.
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interaction across disease stages and across clinical and
biological AD-related markers. Comparing results among
diagnostic groups enabled us to discern a pattern of
effects whereby the adverse effect of APOE-ε4 on brain
structure/function manifests in NC men but not until clinical
disease stages in women. We also revealed important sex
differences in AD-related markers regardless of APOE-ε4
status. The female advantage in verbal memory in
conjunction with higher greater Ab pathology in NC women
versus NCmen suggests that women may be better equipped
to compensate for disease pathology and maintain their
verbal memory advantage.
APOE-ε4 status is a common selection criterion for
intervention trials in preclinical AD. Considering that men
and women may differ in the strength and trajectory of
APOE-ε4 effects, failure to account for sex differences in
APOE-ε4 effects on study outcomes could complicate
interpretation of trials. Our findings may help to explain
inconsistencies in the literature regarding APOE-ε4 effects
on AD-related markers, particularly during the preclinical
phase, and offer insight into biological mechanisms
underlying sex differences in APOE-ε4–associated AD risk.Acknowledgments
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1. Systemic review: Apolipoprotein E (APOE)-ε4
genotype may confer a greater risk for Alzheimer’s
disease (AD) in women than in men. We are the first
to examine the moderating role of sex on the effects
of APOE-ε4 on multiple AD-related markers at all
disease stages.
2. Interpretation: Sex differences in the adverse effect
of APOE-ε4 varied by AD-related marker and
disease stage. Effects of APOE-ε4 on hippocampal
volume and brain metabolism manifested in normal
control men, whereas these effects did not manifest
in women until mild cognitive impairment (MCI). In
AD dementia, APOE-ε4 related to greater amyloid-b
burden in men only.
3. Future directions: APOE-ε4 status is a common
selection criterion for intervention trials in preclini-
cal AD. Considering that the strength and trajectory
of APOE-ε4 effects differ in men and women, failure
to account for sex differences in APOE-ε4 effects
could complicate interpretation of trial findings.References
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